Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 2:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 31,368 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Dose 2 Clear all
Completed Phase 3 Interventional Results available

Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects

NCT00360568
View directory record Official record
Conditions
Dyskinesias, Parkinson's Disease, Severe Motor Fluctuations
Interventions
Levodopa-carbidopa intestinal gel, CADD-Legacy® 1400 ambulatory infusion pump, PEG tube, J-tube
Drug · Device
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
30 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
16
States / cities
Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2015 · Synced Oct 25, 2026, 2:07 PM EDT
Completed Phase 1 Interventional

A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease

NCT05521191
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease, ADPKD, Polycystic Kidney, Autosomal Dominant
Interventions
RGLS8429, Placebo
Drug
Lead sponsor
Regulus Therapeutics Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
21
States / cities
Mesa, Arizona • Los Angeles, California • New Haven, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Oct 25, 2026, 2:07 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Clinical Trial to Evaluate the Effects of an Omega-3-containing Supplement on DHA and EPA Levels in the Blood

NCT07753174
View directory record Official record
Conditions
Omega-3 Deficiency, DHA and EPA Blood Levels, Cardiovascular Health, Cognitive Health
Interventions
Omega Active Supplement
Dietary Supplement
Lead sponsor
Revive Active
Industry
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 25, 2026, 2:07 PM EDT
Recruiting Phase 2Phase 3 Interventional

Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation

NCT07092618
View directory record Official record
Conditions
Longevity, GLP-1, Geroscience, Aging
Interventions
Metformin, Rapamycin, Naltrexone, Vitamin C
Drug · Dietary Supplement
Lead sponsor
AgelessRx
Industry
Eligibility
40 Years to 85 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Oct 25, 2026, 2:07 PM EDT
Withdrawn Early Phase 1 Interventional

Androgen Regulation of Priapism in Sickle Cell Disease

NCT01940718
View directory record Official record
Conditions
Priapism, Sickle Cell Disease, Hypogonadism
Interventions
Transdermal Androgel
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 50 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Oct 25, 2026, 2:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2216684 and Warfarin in Healthy Subjects

NCT01263119
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Warfarin, LY2216684
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Oct 25, 2026, 2:07 PM EDT
Completed Phase 2 Interventional Results available

A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus

NCT05048719
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
LY3502970, Dulaglutide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
383 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
20
States / cities
Anaheim, California • Huntington Park, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Oct 25, 2026, 2:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Investigate the Effects of AZD6140 in Patients With Renal Impairment and in Healthy Volunteers

NCT00733265
View directory record Official record
Conditions
Renal Impairment
Interventions
AZD6140
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
4
States / cities
Phoenix, Arizona • Anaheim, California • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2010 · Synced Oct 25, 2026, 2:07 PM EDT
Completed Phase 3 Interventional Results available

A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT03038100
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms
Interventions
Paclitaxel, Carboplatin, Atezolizumab, Bevacizumab, Atezolizumab Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
127
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 101 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2023 · Synced Oct 25, 2026, 2:07 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of 5 mg Piolocarpine Tablets Under Fed Conditions

NCT00601211
View directory record Official record
Conditions
Dry Mouth
Interventions
Pilocarpine
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 25, 2026, 2:07 PM EDT
Terminated Phase 1 Interventional

TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation

NCT01300611
View directory record Official record
Conditions
Double Cord Blood Transplant, Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Myelofibrosis, Acute Lymphoblastic Leukemia, Chronic Myelocytic Leukemia, Non Hodgkins Lymphoma, Hodgkins Lymphoma, Chronic Lymphocytic Leukemia
Interventions
TXA127 300 mcg/kg/day, TXA127 1000 mcg/kg/day
Drug
Lead sponsor
Tarix Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 25, 2026, 2:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pilot Study: Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators

NCT01988311
View directory record Official record
Conditions
Psilocybin, Hallucinogens, Pharmacologic Actions, Central Nervous System Agents, Therapeutic Uses, Psychotropic Drugs
Interventions
psilocybin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
25 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Oct 25, 2026, 2:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics of Linzagolix in Female Subjects With Normal and Impaired Renal Function

NCT03961932
View directory record Official record
Conditions
Renal Impairment, Healthy Participants
Interventions
Linzagolix
Drug
Lead sponsor
ObsEva SA
Industry
Eligibility
18 Years and older · Female only
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Orlando, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 5, 2020 · Synced Oct 25, 2026, 2:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immune Response to a Respiratory Syncytial Virus (RSV) Vaccine in Adults, RSV-Seropositive Children, and RSV-Seronegative Infants and Children

NCT01459198
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV MEDI ΔM2-2 vaccine, Placebo vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 49 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 15, 2015 · Synced Oct 25, 2026, 2:07 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Switch to Ticagrelor in Critical Limb Ischemia Anti-platelet Study

NCT02091921
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
Ticagrelor
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 80 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 19, 2019 · Synced Oct 25, 2026, 2:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Evinacumab (REGN1500) in Caucasian and in Japanese Healthy Volunteers

NCT03146416
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Evinacumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2018 · Synced Oct 25, 2026, 2:07 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of the Safety and Anesthetic Effect of AG-920 Topical Ophthalmic Solution

NCT04829344
View directory record Official record
Conditions
Anesthesia, Local
Interventions
AG-920, Placebo
Drug
Lead sponsor
American Genomics, LLC
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
McAllen, Texas
Source: ClinicalTrials.gov public record
Updated Oct 10, 2024 · Synced Oct 25, 2026, 2:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Safety and Pharmacokinetics of JNJ-38518168 in Japanese and Caucasian Male Participants and the Effect of JNJ-38518168 on the Blood Levels of Midazolam

NCT01442532
View directory record Official record
Conditions
Healthy Male Volunteer
Interventions
JNJ-38518168 (30 mg), JNJ-38518168 (10 mg), JNJ-38518168 (3 mg), Placebo, Midazolam and JNJ-38518168
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2013 · Synced Oct 25, 2026, 2:07 PM EDT
Completed Phase 2 Interventional

Study to Evaluate Efficacy and Safety of Ropanicant in MDD Patients

NCT06836063
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
Ropanicant, Placebo
Drug
Lead sponsor
Suven Life Sciences Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
35
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Anaheim, California + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 25, 2026, 2:07 PM EDT
Completed Phase 3 Interventional Results available

Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)

NCT03904693
View directory record Official record
Conditions
Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
Interventions
FDC macitentan/tadalafil, Macitentan 10 mg, Tadalafil 40 mg, Placebo FDC, Placebo macitentan, Placebo tadalafil
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
26
States / cities
Fullerton, California • Los Angeles, California • Atlanta, Georgia + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 25, 2026, 2:07 PM EDT
Recruiting Phase 2 Interventional

Vorinostat for Graft-versus-host Disease (GVHD) Prevention in Non-Malignant Adolescent and Young Adults (AYA) Population

NCT06995521
View directory record Official record
Conditions
GVHD
Interventions
Vorinostat
Drug
Lead sponsor
Sung Won Choi
Other
Eligibility
1 Year to 26 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 25, 2026, 2:07 PM EDT
Terminated Phase 1 Interventional

Leflunomide in Mild COVID-19 Patients

NCT04361214
View directory record Official record
Conditions
COVID-19
Interventions
Leflunomide
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Oct 25, 2026, 2:07 PM EDT
Active, not recruiting Early Phase 1 Interventional

Mechanistic Studies of Nicotinamide Riboside in Human Heart Failure

NCT04528004
View directory record Official record
Conditions
Heart Failure, Systolic, Heart Failure NYHA Class IV, Metabolic Disturbance
Interventions
Nicotinamide riboside, Placebo
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Oct 25, 2026, 2:07 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Effect of the Combination of Umeclidinium (UMEC) and Vilanterol (VI) on Exercise Endurance Time (EET) in Participants With Chronic Obstructive Pulmonary Disease (COPD)

NCT02275052
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
UMEC/VI DPI, Placebo DPI, Albuterol/salbutamol MDI
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
10
States / cities
Jasper, Alabama • Saint Charles, Missouri • Charlotte, North Carolina + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Oct 25, 2026, 2:07 PM EDT